Syngene Intl Peer Comparison

NSE: SYNGENE | BSE: 539268

₹377.50

₹-7.65 (-1.99%)

As on 22-Sep-2026IST

Market cap

₹15,247 Cr

Revenue (TTM)

₹3,600 Cr

P/E Ratio

P/B Ratio

3.2

Div. Yield

0.3 %

Edit

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	15,247	35,504	27,675	26,306	27,978
Revenue (₹ Cr)	3,600	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	221.00	414.00	288.22	387.35	-371.81
Net Margin (%)	6.01	11.23	14.79	26.01	-3.93
RoE (%)	5.62	8.38	29.77	25.18	-3.85
Price to Earnings	68.99	86.81	96.02	68.11	--
Price-To-Book	3.22	7.05	20.62	15.25	3.50

Income Statement (₹ Cr)

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	3,600.20	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	3,678.50	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	2,797.30	2,792.00	1,485.56	919.25	8,195.15
EBITDA	802.90	772.00	450.24	542.56	1,010.13
Depreciation	453.90	226.00	50.83	37.68	857.51
EBIT	349.00	546.00	399.41	504.88	152.62
Interest	46.80	217.00	40.84	3.77	342.73
Other Income	78.30	122.00	12.78	27.45	244.31
Exceptional Items	-90.10	12.00	0.00	0.00	-216.88
Profit before Tax	290.40	463.00	371.35	528.56	-162.68
Provision for Tax	69.40	49.00	83.14	141.21	209.13
Profit after Tax	221.00	414.00	288.22	387.35	-371.81

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	4,839.10	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	663.30	1,712.00	202.03	42.40	5,044.14
Current Liabilities	1,552.30	1,622.00	835.87	230.82	4,758.28
Total Liabilities	7,054.70	8,578.00	2,326.71	1,983.96	17,723.32

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	4,046.90	5,343.00	519.60	1,026.85	10,211.52
Current Assets	2,142.80	2,606.00	1,681.81	881.27	7,191.66
Total Assets	7,054.70	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	9.40	2,125.00	259.37	26.49	5,495.48
Net Current Assets	590.50	984.00	845.94	650.46	2,433.38
Contingent Liabilities	536.50	768.26	19.09	17.25	95.72

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	915.20	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	-860.40	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	-215.00	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	-160.20	95.00	78.39	30.33	787.59

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	9.48	6.79	29.22	32.42	1.24
ROE (%)	5.62	8.38	29.77	25.18	-3.85
ROA (%)	3.19	4.94	24.77	21.93	-2.21
EBIT Margin (%)	9.69	15.32	20.63	34.54	1.66
Net Margin (%)	6.01	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-3.41	18.37	46.65	40.90	0.78
EBIT Growth (%)	-45.08	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	-56.43	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-46.98	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	2.11	13.47	144.31	26.03	0.33

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	56.54	89.10	94.55	68.11	-89.41
Price / Book Value	3.22	7.05	20.62	15.25	3.50
Dividend Yield (%)	0.33	0.00	0.09	0.08	0.00
EV/EBITDA	17.40	47.88	61.28	48.12	31.80
Market Cap (₹ Cr)	15,723.10	19,071.62	12,753.19	20,944.75	18,108.89

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.00	0.31	0.11	0.02	0.53
Short term debt to equity ratio	0.00	0.09	0.05	0.02	0.09
Current Ratio	1.38	1.61	2.01	3.82	1.51
Quick Ratio	1.29	1.06	1.14	2.82	0.87
Interest Coverage	7.21	3.13	10.09	141.16	0.53

	Syngene Intl	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	14.13	16.50	26.28	24.80	23.44
Asset Turnover	0.52	0.43	1.66	0.83	0.55
Receivable days	50.33	58.75	40.13	88.98	78.20
Inventory Days	14.43	75.82	60.29	56.04	93.30
Payable days	17,487.50	186.21	232.47	99.95	226.14
Cash Conversion Cycle	-17,422.74	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.